1. Technology overview
AI Medical Service Inc. (AIM) was founded on September 1, 2017 and is headquartered in Tokyo, Japan, with a branch in Singapore and offices in the United States. The company develops endoscopic AI with the mission of reducing gastrointestinal cancer deaths by catching cancers that endoscopy might otherwise miss.
gastroAI model-G3 supports lesion detection during upper GI endoscopy. It analyzes endoscopic video in real time, flags areas that may be early gastric cancer or adenoma with up to three markers, uses multi-frame analysis to limit false positives, and pauses automatically when images are unsuitable. It is positioned as an examiner's aid, not a diagnostic decision tool.
2. Highlighted features & specifications
- Real-time video analysis: Analyzes endoscopic video during upper GI examination.
- Lesion markers: Overlays up to three markers on regions that may be early gastric cancer or adenoma.
- Multi-frame analysis: Aims for high detection while reducing false positives.
- Image quality check: Automatically detects unsuitable images and pauses analysis.
- Examiner aid design: Supports detection only, leaving diagnosis and treatment decisions to physicians.
- Regulatory coverage: Approved in Japan in May 2026 and in Thailand in 2025.
3. Potential application
Endoscopy departments of large Vietnamese hospitals can use real-time lesion flagging as a second reader during upper GI screening. Health-check centers can use it to standardize detection quality across less experienced endoscopists.
4. Benefits
Assists endoscopists in spotting early gastric cancer and adenoma during live examination. Retrospective study on 1,099 samples reported sensitivity of 94.6% and specificity of 94.3% (company-reported). Multi-frame analysis aims to keep false positives low. Approved as a medical device in Japan, with Thailand approval in 2025.
5. Market trends & opportunities
Gastric cancer detection depends heavily on endoscopist skill, and Asian health systems are adopting AI to reduce missed lesions. AIM's Thailand approval in 2025 and Singapore branch indicate a push into Southeast Asian markets, which may extend to Vietnam's endoscopy centers.
6. Other information
Founded September 1, 2017, Tokyo; Singapore branch and US offices; about 100 employees (September 2025); capital of 13.8 billion yen including reserves. Thailand FDA approval in 2025; Japan approval in May 2026.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE









































